未稀释静脉推注左乙拉西坦的不良事件
该前瞻性观察性队列研究纳入了在大型社区教学医院急诊科接受快速未稀释静脉推注左乙拉西坦(剂量最高4500 mg)的成人患者,共250例患者被纳入分析。主要终点为任何预设不良事件的发生率,结果为5.6%(14例),最常见为注射部位反应(9/14);临床相关低血压、心动过速和高血压共5例。对于正在癫痫发作的患者,79%(15/19)实现发作终止,从开医嘱到给药完成的中位时间为12分钟。作者认为急诊快速给予未稀释静脉推注左乙拉西坦不良事件较少。
要点
- 急诊成人快速未稀释静脉推注左乙拉西坦(剂量最高4500 mg)任何预设不良事件发生率为5.6%(14/250)。
- 不良事件以注射部位反应最常见,占9/14例;临床相关低血压、心动过速和高血压共5例。
- 正在癫痫发作的患者中79%(15/19)实现发作终止。
- 活动性癫痫发作患者从开医嘱到给药完成的中位时间为12分钟。
- 作者结论:急诊快速给予未稀释静脉推注左乙拉西坦与少量不良事件相关。
适用人群与场景
- 在大型社区教学医院急诊科接受快速未稀释静脉推注左乙拉西坦的成人患者,剂量最高4500 mg;共250例患者纳入分析。
处置流程与药物剂量
- 快速给予未稀释静脉推注左乙拉西坦,剂量最高4500 mg,用于急诊成人患者;活动性癫痫发作患者从开医嘱到给药完成的中位时间为12分钟。
研究设计与关键结果
- 研究类型:前瞻性观察性队列研究;人群:在大型社区教学医院急诊科接受快速未稀释静脉推注左乙拉西坦(剂量最高4500 mg)的成人患者;共开具321剂静脉推注左乙拉西坦,涉及318例患者,最终250例患者纳入分析。
- 主要终点:任何预设不良事件发生率为5.6%(14/250)。
- 不良事件类型:注射部位反应最常见(9/14);临床相关低血压、心动过速和高血压共5例。
- 活动性癫痫发作患者:79%(15/19)实现发作终止;从开医嘱到给药完成的中位时间为12分钟。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为急诊快速给予未稀释静脉推注左乙拉西坦与少量不良事件相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients who experience a seizure, the seizure duration is a strong indicator of prognosis. Thus, reducing time to antiepileptic medications in patients who are actively seizing is critical. While findings from retrospective studies suggest that the rapid administration of undiluted intravenous (IV) levetiracetam may be safe, some gaps in the literature remain.
OBJECTIVE: The purpose of this research study was to prospectively assess adverse events associated with the rapid administration of undiluted IV levetiracetam.
METHODS: This was a prospective, observational cohort study of adult patients who received rapid administration of undiluted IV levetiracetam at doses up to 4500 mg in the emergency department (ED) of a large community, teaching hospital. The primary endpoint was the incidence of any pre-defined adverse event. Secondary endpoints included the incidence of each type of adverse event, the incidence of seizure termination, and the time to completion of drug administration in patients actively seizing at the time of study inclusion.
RESULTS: A total of 321 doses of IV push levetiracetam were ordered for 318 patients and 250 patients were subsequently included. Fourteen (5.6%) patients experienced an adverse event, most commonly due to injection site reactions (9/14). Clinically relevant hypotension, tachycardia, and hypertension occurred in five patients. For actively seizing patients, 79% (15/19) achieved seizure termination and the median time from medication order to completion of therapy was 12 min.
CONCLUSION: This study found that the rapid administration of undiluted IV levetiracetam in ED patients was associated with few adverse events.
参考来源
- Summerlin JA, Scaturo N, Lund JA, et al. Adverse events of undiluted intravenous push levetiracetam. Am J Emerg Med. 2023. PMID: 37708595. doi:10.1016/j.ajem.2023.08.046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。